Uncategorized
Biotech startup Tevogen Bio is going public in a $1.2 billion SPAC deal in the US
While generative AI continues to dominate the headlines, things have been relatively quiet on the blank-check merger front. But that doesn’t mean special purpose acquisition company (SPAC) deals aren’t happening. It’s just that the number of SPAC deals has dwindled
While generative AI continues to dominate the headlines, things have been relatively quiet on the blank-check merger front. But that doesn’t mean special purpose acquisition company (SPAC) deals aren’t happening. It’s just that the number of SPAC deals has dwindled […]